Precision Medicine in Cytopathology.
Ancillary testing
Cytopathology
Immunohistochemistry
Next-generation sequencing
Precision medicine
Predictive biomarkers
Journal
Surgical pathology clinics
ISSN: 1875-9157
Titre abrégé: Surg Pathol Clin
Pays: United States
ID NLM: 101491209
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
medline:
12
8
2024
pubmed:
12
8
2024
entrez:
12
8
2024
Statut:
ppublish
Résumé
Over the last decade, cancer diagnostics has undergone a notable transformation with increasing complexity. Minimally invasive diagnostic tests, driven by advanced imaging and early detection protocols, are redefining patient care and reducing the need for more invasive procedures. Modern cytopathologists now safeguard patient samples for vital biomarker and molecular testing. In this article, we explore ancillary testing modalities and the role of biomarkers in organ-specific contexts, underscoring the transformative impact of precision medicine. Finally, the advent of more than 80 Food and Drug Administration-approved predictive biomarkers signals a new era, guiding cancer care toward personalized and targeted strategies.
Identifiants
pubmed: 39129134
pii: S1875-9181(24)00013-8
doi: 10.1016/j.path.2024.04.002
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
329-345Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Acknowledgments Author DBA and this manuscript were supported by the Biospecimen Procurement & Translational Pathology Shared Resource Facility of the University of Kentucky Markey Cancer Center (P30CA177558). Disclosure The other authors have no relevant conflicts of interest to disclose.